drugset

drugset / Trial / NCT04722627

Study of AT-752 in Healthy Subjects

NCT04722627 ↗

Phase 1 Completed 65 enrolled Atea Pharmaceuticals, Inc.

RandomizedSequentialTriple-blindTreatment

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects

Timeline

Start: 2021-03-09
Primary completion: 2021-11-14
Completion: 2021-11-14

Publications

Bouzidi HS, De Lamballerie X, Touret F. Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies. Emerg Microbes Infect. 2026 Dec;15(1):2686471. doi: 10.1080/22221751.2026.2686471. Epub 2026 Jun 21.
Zhou X-J, Lickliter J, Montrond M, Ishak L, Pietropaolo K, James D, Belanger B, Horga A, Hammond J. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrob Agents Chemother. 2024 May 2;68(5):e0161523. doi: 10.1128/aac.01615-23. Epub 2024 Mar 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AT-752	Other / unclassified	250 mg	Oral
Subject	AT-752	Other / unclassified	500 mg	Oral
Subject	AT-752	Other / unclassified	750 mg	Oral
Subject	AT-752	Other / unclassified	1000 mg	Oral
Subject	AT-752	Other / unclassified	1500 mg	Oral

Indications